Harvard's Fishman Focuses Novartis on Rare Disease to Find Arthritis Cure

(Bloomberg) -- Mark Fishman says Novartis AG's most-
productive research may come from a disease called Muckle-Wells
that affects 1,000 people.

Fishman, Harvard University's top cardiologist and
Novartis's head scientist, is determined to uncover whether rare
diseases, such as Muckle-Wells, share some of the same biological
makeup as cancer and arthritis. Since he joined Switzerland's
largest drugmaker four years ago, Fishman has sought to identify
``disease pathways'' in unusual disorders that may help lead
scientists to drugs for more common ones.


Read more at Bloomberg Exclusive News